<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41936">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01997424</url>
  </required_header>
  <id_info>
    <org_study_id>JWGUHMED1-007</org_study_id>
    <nct_id>NCT01997424</nct_id>
  </id_info>
  <brief_title>ASSOCIATION OF NON-ALCOHOLIC FATTY LIVER DISEASE AND DIABETES MELLITUS</brief_title>
  <official_title>ASSOCIATION OF NON-ALCOHOLIC FATTY LIVER DISEASE AND DIABETES MELLITUS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johann Wolfgang Goethe University Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johann Wolfgang Goethe University Hospitals</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the association of non-alcoholic fatty liver disease and diabetes
      mellitus. Patients presenting in our clinic with Diabetes mellitus type 1 or 2 will receive
      the following examination:

        -  Transient Elastography and Controlled Attenuation Parameter using the FibroScan

        -  blood examination including biochemical markers The statistically calculated sample
           size needed is 340 patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Steatosis</measure>
    <time_frame>one day</time_frame>
    <safety_issue>No</safety_issue>
    <description>•	Evaluating the presence of liver steatosis in patients with diabetes mellitus using the ultrasound-based method &quot;Controlled Attenuation Parameter&quot;, which is integrated in the FibroScan machine and can non-invasively quantify liver steatosis (Steatosis fibrosis scores I-III [ Designated as safety issue: No ]; Steatosis scores: 0 = &lt;5% I = 5-33% II = 33-66% III = &gt;66%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fibrosis</measure>
    <time_frame>one day</time_frame>
    <safety_issue>No</safety_issue>
    <description>•	Evaluation of the prevalence of liver fibrosis using transientelastography (FibroScan) and serological markers in patients with diabetes mellitus (Liver fibrosis scores I-IV (METAVIR) [ Designated as safety issue: No ]; METAVIR fibrosis scores: I = mild fibrosis II = significant fibrosis III = advanced fibrosis IV = cirrhosis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steatosis (serum)</measure>
    <time_frame>one day</time_frame>
    <safety_issue>No</safety_issue>
    <description>•	Evaluating the prevalence of liver steatosis using serum steatosis markers in patients with diabetes mellitus</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">340</enrollment>
  <condition>Non-alcoholic Fatty Liver Disease (NAFLD)</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Controlled Attenuation Parameter (CAP), Echosens, Paris, France</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FibroScan, Echosens, Paris, France</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 18 years and older

          -  Written informed consent

          -  Diabetes mellitus type 1 or 2

        Exclusion Criteria:

          -  Patients with mental diseases

          -  Pregnancy or lactation

          -  Ascites

          -  Continued alcohol consumption (&gt; 21 drinks/week for male and &gt; 14 drinks/week for
             female patients)

          -  Chronic liver disease (viral hepatitis, autoimmune hepatitis, PBC, PSC,
             hemochromatosis, M Wilson)

          -  Hepatocellular carcinoma/ Liver metastasis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mireen Friedrich-Rust, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Frankfurt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mireen Friedrich-Rust, MD</last_name>
    <phone>496963015122</phone>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Frankfurt</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mireen Friedrich-Rust, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 27, 2013</lastchanged_date>
  <firstreceived_date>October 23, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johann Wolfgang Goethe University Hospitals</investigator_affiliation>
    <investigator_full_name>Johannes Vermehren</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
